melanoma: nuances of braf/mek combinations in the front line
Published 7 years ago • 2K plays • Length 9:49Download video MP4
Download video MP3
Similar videos
-
6:08
braf-mutant melanoma: frontline decisions
-
1:33
dr. paul chapman on braf and mek inhibitor combination for advanced melanoma
-
6:22
braf and mek in melanoma
-
6:08
braf-mutant melanoma: frontline decisions
-
8:47
braf/mek inhibitors in metastatic melanoma
-
8:40
melanoma: braf/mek targeted therapy
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
9:24
anti-pd1 monotherapy or combination with ipi after braf/mek inhibitors in braf-mutant melanoma
-
1:19
dr. postow on braf and mek inhibitor combination studies in melanoma
-
0:52
dr. kudchadkar on combining braf and mek inhibitors to treat melanoma
-
4:07
understanding resistance to combined braf and mek inhibiton in melanoma and the significance of cdk4
-
6:33
treatment of braf-mutant metastatic melanoma
-
1:28
jeffrey weber, md, phd: the impact of braf/mek inhibitors in melanoma
-
1:40
dr. robert on the phase iii combi-v study in braf-mutant melanoma
-
9:43
sequencing dual braf-mek inhibition and immunotherapy
-
1:09
rationale for mek/braf combinations in melanoma
-
7:23
melanoma: braf/mek-inhibitors as adjuvant therapy
-
10:08
emerging approaches for braf-mutant metastatic melanoma
-
1:06:50
everything you want to know about the braf/mek combination